期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 60, 期 12, 页码 4780-4804出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.6b01595
关键词
-
资金
- EU: COST-Action
- EPICHEM-BIO [CM1406]
- FP7, BLUEPRINT [282510]
- A-PARADDISE [602080]
- PRIN [2012CTAYSY, 20152TE5PK]
- AIRC Fondazione Cariplo TRIDEO [17515]
Current therapies for human parasite infections rely on a few drugs, most of which have severe side effects, and their helpfulness is being seriously compromised by the drug resistance problem. Globally, this is pushing discovery research of antiparasitic drugs toward new agents endowed with new mechanisms of action. By using a drug repurposing strategy, histone deacetylase inhibitors (HDACi), which are presently clinically approved for cancer use, are now under investigation for various parasite infections. Because parasitic Zn2+- and NAD(+)-dependent HDACs play crucial roles in the modulation of parasite gene expression and many of them are pro-survival for several parasites under various conditions, they are now emerging as novel potential antiparasitic targets. This Perspective summarizes the state of knowledge of HDACi (both class I/II HDACi and sirtuin inhibitors) targeted to the main human parasitic diseases (schistosomiasis, malaria, trypanosomiasis, leishmaniasis, and toxoplasmosis) and provides visions into the main issues that challenge their development as antiparasitic agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据